Progyny FY2026 EPS Estimate Increased by Leerink Partnrs

Progyny, Inc. (NASDAQ:PGNY - Free Report) - Analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for shares of Progyny in a research report issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.98 for the year, up from their previous forecast of $0.94. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Progyny's current full-year earnings is $0.60 per share.

Other equities research analysts have also issued reports about the company. BTIG Research raised Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a research note on Monday, March 31st. Canaccord Genuity Group decreased their target price on Progyny from $23.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Finally, Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price for the company in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $24.09.

Progyny Price Performance

Shares of PGNY traded down $0.40 during trading hours on Thursday, hitting $23.21. 739,927 shares of the company were exchanged, compared to its average volume of 1,723,180. The company has a market capitalization of $1.99 billion, a PE ratio of 40.72, a PEG ratio of 2.43 and a beta of 1.31. The firm has a fifty day simple moving average of $21.81 and a 200-day simple moving average of $21.53. Progyny has a one year low of $13.39 and a one year high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The firm had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. Progyny had a net margin of 4.33% and a return on equity of 10.90%. The business's revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 earnings per share.

Hedge Funds Weigh In On Progyny

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC bought a new position in Progyny during the first quarter worth $354,000. GAMMA Investing LLC increased its holdings in Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after buying an additional 3,768 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in shares of Progyny by 18.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,675 shares of the company's stock worth $775,000 after purchasing an additional 5,459 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Progyny by 129.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,967 shares of the company's stock worth $344,000 after purchasing an additional 11,268 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Progyny in the 4th quarter worth about $229,000. Institutional investors own 94.93% of the company's stock.

Insider Transactions at Progyny

In related news, Director Cheryl Scott sold 2,675 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director owned 14,112 shares of the company's stock, valued at approximately $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 9.40% of the company's stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.